Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight [Yahoo! Finance]
Inhibrx, Inc. (INBX)
Company Research
Source: Yahoo! Finance
diagnosis, treatment advancements, increased awareness, the launch of emerging therapies such as Ozekibart (INBRX-109) (Inhibrx Biosciences), TIBSOVO (ivosidenib) (Servier), LY3410738 (Eli Lilly), and others, and global healthcare spending, reports DelveInsight. LAS VEGAS Feb. 26, 2026 /PRNewswire/ -- Recently published chondrosarcoma Market Insights report includes a comprehensive understanding of current treatment practices, chondrosarcoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. DelveInsight Logo Chondrosarcoma Market Summary The total chondrosarcoma treatment market size is expected to grow positively by 2036 in the leading markets. The United States accounts for the largest market size of chondrosarcoma, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and J
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Inhibrx Announces Participation in Upcoming Scientific Conference [Yahoo! Finance]Yahoo! Finance
- Inhibrx Announces Participation in Upcoming Scientific ConferencePR Newswire
- Inhibrx Biosciences (NASDAQ:INBX) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too [Seeking Alpha]Seeking Alpha
- Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts [Yahoo! Finance]Yahoo! Finance
INBX
Earnings
- 8/13/25 - Beat
INBX
Sec Filings
- 2/23/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- 2/11/26 - Form SCHEDULE
- INBX's page on the SEC website